On the other hand, several studies have found that PTRF promotes progression and resistance to treatment in breast cancer, pancreatic cancer, glioblastomas, and colorectal cancer (Yi et al., 2013; Wang et al., 2014). Here, CAVIN1 is linked to glioblastoma.